Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19656242 | 0.92 | ELANE (0.43) | ELANECYP3A4CYP2C9RORC | |
| SCHEMBL19639771 | 0.87 | ELANE (0.40) | ELANECYP3A4CYP2C9RORC | |
| SCHEMBL19639779 | 0.85 | ELANE (0.45) | ELANECYP3A4CYP2C9RORC | |
| SCHEMBL19640018 | 0.84 | ELANE (0.40) | ELANECYP3A4CYP2C9RORC | |
| SCHEMBL19651233 | 0.83 | ELANE (0.42) | ELANECYP3A4CYP2C9RORC | |
| SCHEMBL19684402 | 0.81 | ALOX15 (0.35) | CYP3A4 | |
| SCHEMBL19640139 | 0.80 | ELANE (0.46) | ELANECYP3A4CYP2C9RORC | |
| SCHEMBL19640081 | 0.79 | ELANE (0.49) | ELANECYP3A4CYP2C9RORC | |
| SCHEMBL19640103 | 0.79 | ELANE (0.40) | ELANECYP3A4CYP2C9RORC | |
| SCHEMBL19640097 | 0.79 | ELANE (0.46) | ELANECYP3A4CYP2C9RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464268-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2020-03-11 | — | — | EP | disclosed |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| WO-2017207432-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-12-07 | — | — | WO | disclosed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340611-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | ELANE 2/4885CYP3A4 1599/4885CYP2C9 3005/4885 |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | SERPINB1, ELANE, EPX | ELANE 2/4885CYP3A4 1162/4885CYP2C9 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.